Literature DB >> 14678629

Leishmania/HIV co-infections: epidemiology in Europe.

P Desjeux1, J Alvar.   

Abstract

As the AIDS pandemic spreads to rural areas and human visceral leishmaniasis (VL) becomes more common in suburban areas, there is an ever greater degree of overlap between the geographical distributions of the two diseases and, in consequence, an increasing incidence of Leishmania/HIV co-infection. Cases of the co-infection have been reported from 35 countries around the world but most have been recorded in south-western Europe. There has been a total of 1911 cases detected in Spain, France, Italy and Portugal. The incidence of Leishmania/HIV co-infection is expected to continue increasing in eastern Africa but to fall in south-western Europe as increasing numbers of HIV-positives in the latter region are given the new, highly active, antiretroviral therapy (HAART). In 1998, a world-wide network of surveillance for the co-infection, which now includes 28 member institutions, was established by the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS). In south-western Europe, the surveillance system is based on 16 institutions and is already well established. The systematic use of standardized and recently computerized case-report forms, a central international registry at the WHO's headquarters in Geneva, and the use of a geographical information system (GIS) for mapping and monitoring the co-infections have together improved the overall quality of the epidemiological data-gathering. All member institutions of the global network report to the WHO on an annual basis. The data collected are then analysed and periodically disseminated through international publications. The GIS allows the relevant epidemiological and demographic data-sets to be integrated and permits all detected cases of co-infection to be mapped down to locality level. The system also allows the spatial distribution of cases to be visualised and analysed and the geographical spread of the co-infection to be monitored over time. The risk posed by co-infected patients, as a source of Leishmania infection for the sandflies feeding on them, has recently been confirmed. The parasites and HIV may also be transmitted as the result of needle-sharing among intravenous-drug users.

Entities:  

Mesh:

Year:  2003        PMID: 14678629     DOI: 10.1179/000349803225002499

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  86 in total

Review 1.  Diagnosis of visceral leishmaniasis: developments over the last decade.

Authors:  Gurumurthy Srividya; Arpita Kulshrestha; Ruchi Singh; Poonam Salotra
Journal:  Parasitol Res       Date:  2011-11-09       Impact factor: 2.289

2.  Elevated levels of soluble non-classical major histocompatibility class I molecule human leucocyte antigen (HLA)-G in the blood of HIV-infected patients with or without visceral leishmaniasis.

Authors:  L Donaghy; F Gros; L Amiot; C Mary; A Maillard; C Guiguen; J-P Gangneux
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

Review 3.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 4.  The genetics of Leishmania virulence.

Authors:  Eugenia Bifeld; Joachim Clos
Journal:  Med Microbiol Immunol       Date:  2015-06-06       Impact factor: 3.402

5.  Protease expression by microorganisms and its relevance to crucial physiological/pathological events.

Authors:  André Luis Souza Dos Santos
Journal:  World J Biol Chem       Date:  2011-03-26

Review 6.  Chemotherapeutics of visceral leishmaniasis: present and future developments.

Authors:  Shyam Sundar; Anup Singh
Journal:  Parasitology       Date:  2017-12-07       Impact factor: 3.234

Review 7.  Leishmaniasis treatment--a challenge that remains: a review.

Authors:  Dilvani O Santos; Carlos E R Coutinho; Maria F Madeira; Carolina G Bottino; Rodrigo T Vieira; Samara B Nascimento; Alice Bernardino; Saulo C Bourguignon; Suzana Corte-Real; Rosa T Pinho; Carlos Rangel Rodrigues; Helena C Castro
Journal:  Parasitol Res       Date:  2008-06       Impact factor: 2.289

8.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05

Review 9.  Spread of vector-borne diseases and neglect of Leishmaniasis, Europe.

Authors:  Jean-Claude Dujardin; Lenea Campino; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Ketty Soteriadou; Apostolos Mazeris; Yusuf Ozbel; Marleen Boelaert
Journal:  Emerg Infect Dis       Date:  2008-07       Impact factor: 6.883

10.  Cryptic Leishmania infantum infection in Italian HIV infected patients.

Authors:  Claudia Colomba; Laura Saporito; Fabrizio Vitale; Stefano Reale; Giustina Vitale; Alessandra Casuccio; Manlio Tolomeo; Daniela Maranto; Raffaella Rubino; Paola Di Carlo; Lucina Titone
Journal:  BMC Infect Dis       Date:  2009-12-10       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.